Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
19,368,854
-
Share change
-
+50,614
-
Total reported value
-
$80,575,000
-
Put/Call ratio
-
78%
-
Price per share
-
$4.16
-
Number of holders
-
39
-
Value change
-
+$347,478
-
Number of buys
-
16
-
Number of sells
-
16
Institutional Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q3 2019
As of 30 Sep 2019,
AVADEL PHARMACEUTICALS - COM (AVDL) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,368,854 shares.
The largest 10 holders included
BRANDES INVESTMENT PARTNERS, LP, Broadfin Capital, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), BROWN CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Tekla Capital Management LLC, AMERIPRISE FINANCIAL INC, MORGAN STANLEY, DEUTSCHE BANK AG\, and JW Asset Management, LLC.
This page lists
39
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.